Daiichi Sankyo has appointed Antoine Yver, MD, MSc, as Global Head, Oncology Research and Development. In this newly created role, the company noted, Dr. Yver it will report to Glenn Gormley, MD, PhD, Senior Executive Officer and Global Head, Research & Development, Daiichi Sankyo Co., and Chairman of the Board and President, Daiichi Sankyo, and will have responsibility for leading all of the global research and development across the oncology therapeutic area including external investments, internal pipeline decisions, and resourcing requirements. Dr. Yver joins Daiichi Sankyo from AstraZeneca, where he most recently served as Senior Vice President and Head of Oncology, Global Medicines Development, and Global Medicines Development China Lead across all therapeutic areas.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5,525 JPY | -0.11% | +1.86% | +42.64% |
05-15 | Merck to present new oncology data | CF |
05-15 | IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.64% | 68.21B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- 4568 Stock
- News Daiichi Sankyo Co., Ltd.
- Daiichi Sankyo Appoints Dr. Antoine Yver as Global Head, Oncology Research and Development